Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sonnet Biotherapeutics Holdings Inc (SONN)

Sonnet Biotherapeutics Holdings Inc (SONN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,863
  • Shares Outstanding, K 3,066
  • Annual Sales, $ 20 K
  • Annual Income, $ -7,440 K
  • EBIT $ -13 M
  • EBITDA $ -13 M
  • 60-Month Beta 0.58
  • Price/Sales 198.46
  • Price/Cash Flow N/A
  • Price/Book 0.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.56
  • Growth Rate Est. (year over year) +178,292.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1000 +14.55%
on 04/07/25
1.7000 -25.88%
on 04/04/25
-0.1300 (-9.35%)
since 03/17/25
3-Month
1.1000 +14.55%
on 04/07/25
2.0500 -38.54%
on 01/22/25
-0.2800 (-18.18%)
since 01/17/25
52-Week
1.1000 +14.55%
on 04/07/25
16.0000 -92.13%
on 06/10/24
-12.3400 (-90.74%)
since 04/17/24

Most Recent Stories

More News
Sonnet Releases Virtual Investor "What This Means" Segment

SONN : 1.2600 (+2.44%)
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

SONN : 1.2600 (+2.44%)
Sonnet Announces Release of Corporate Update Video

SONN : 1.2600 (+2.44%)
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

SONN : 1.2600 (+2.44%)
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

SONN : 1.2600 (+2.44%)
Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

SONN : 1.2600 (+2.44%)
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

SONN : 1.2600 (+2.44%)
Virtual Investor Releases Next Wave of "Top 5 for '25" On-Demand Videos

- Access video webcasts from all participating companies here

AIM : 0.0949 (-19.37%)
SONN : 1.2600 (+2.44%)
MBRX : 0.8749 (-4.80%)
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

SONN : 1.2600 (+2.44%)
Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

SONN : 1.2600 (+2.44%)

Business Summary

Sonnet BioTherapeutics Holdings Inc. is an oncology-focused biotechnology company with a proprietary platform for biologic drugs of single or bispecific action. Sonnet BioTherapeutics Holdings Inc., formerly known as Chanticleer Holdings Inc., is based in PRINCETON, N.J.

See More

Key Turning Points

3rd Resistance Point 1.3333
2nd Resistance Point 1.3067
1st Resistance Point 1.2833
Last Price 1.2600
1st Support Level 1.2333
2nd Support Level 1.2067
3rd Support Level 1.1833

See More

52-Week High 16.0000
Fibonacci 61.8% 10.3082
Fibonacci 50% 8.5500
Fibonacci 38.2% 6.7918
Last Price 1.2600
52-Week Low 1.1000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar